- Home
- ADN vs RLMD Comparison
ADN vs RLMD Comparison
Compare ADN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- RLMD
- Stock Information
- Founded
- ADN 2006
- RLMD 2004
- Country
- ADN United States
- RLMD United States
- Employees
- ADN N/A
- RLMD N/A
- Industry
- ADN Power Generation
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- RLMD Health Care
- Exchange
- ADN Nasdaq
- RLMD Nasdaq
- Market Cap
- ADN 11.3M
- RLMD 11.5M
- IPO Year
- ADN N/A
- RLMD N/A
- Fundamental
- Price
- ADN $3.51
- RLMD $0.30
- Analyst Decision
- ADN
- RLMD Hold
- Analyst Count
- ADN 0
- RLMD 4
- Target Price
- ADN N/A
- RLMD $4.25
- AVG Volume (30 Days)
- ADN 17.9K
- RLMD 382.7K
- Earning Date
- ADN 12-27-2024
- RLMD 03-27-2025
- Dividend Yield
- ADN N/A
- RLMD N/A
- EPS Growth
- ADN N/A
- RLMD N/A
- EPS
- ADN N/A
- RLMD N/A
- Revenue
- ADN $8,157,000.00
- RLMD N/A
- Revenue This Year
- ADN $2,232.99
- RLMD N/A
- Revenue Next Year
- ADN $91.56
- RLMD N/A
- P/E Ratio
- ADN N/A
- RLMD N/A
- Revenue Growth
- ADN 274.35
- RLMD N/A
- 52 Week Low
- ADN $1.71
- RLMD $0.24
- 52 Week High
- ADN $8.79
- RLMD $5.09
- Technical
- Relative Strength Index (RSI)
- ADN 30.60
- RLMD 50.05
- Support Level
- ADN $3.45
- RLMD $0.26
- Resistance Level
- ADN $4.82
- RLMD $0.32
- Average True Range (ATR)
- ADN 0.45
- RLMD 0.02
- MACD
- ADN -0.15
- RLMD 0.00
- Stochastic Oscillator
- ADN 2.68
- RLMD 67.34
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.